Ekso Bionics (NASDAQ:EKSO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report sent to investors on Saturday. The firm issued a hold rating on the stock.

Several other equities research analysts have also recently weighed in on EKSO. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Ekso Bionics in a research note on Tuesday, January 14th. Lake Street Capital dropped their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th.

Ekso Bionics Stock Down 0.6 %

NASDAQ EKSO opened at $0.57 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The firm has a 50-day simple moving average of $0.63 and a 200 day simple moving average of $0.85. Ekso Bionics has a twelve month low of $0.47 and a twelve month high of $2.16. The stock has a market cap of $12.55 million, a PE ratio of -0.88 and a beta of 1.46.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.